{"id":"NCT00596271","sponsor":"Valneva Austria GmbH","briefTitle":"Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440","officialTitle":"Safety and Immunogenicity of Concomitant Vaccination With IC51 and HARVIX® 1440 in Healthy Subjects. A Single-blind Randomized, Controlled Phase 3 Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-09","primaryCompletion":"2006-07","completion":"2008-08","firstPosted":"2008-01-16","resultsPosted":"2014-05-13","lastUpdate":"2014-05-13"},"enrollment":192,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Japanese Encephalitis"],"interventions":[{"type":"BIOLOGICAL","name":"IC51","otherNames":["Japanese Encephalitis purified inactivated vaccine"]},{"type":"BIOLOGICAL","name":"HAVRIX","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"IC51 and Placebo","type":"ACTIVE_COMPARATOR"},{"label":"HAVRIX and placebo","type":"ACTIVE_COMPARATOR"},{"label":"IC51 and HAVRIX","type":"ACTIVE_COMPARATOR"}],"summary":"The objective is to investigate the immunogenicity of the Japanese Encephalitis vaccine IC51 (JE-PIV) single and concomitant with HAVRIX® 1440","primaryOutcome":{"measure":"Geometric Mean Titer (GMT) at Day 56 for Anti-JEV Neutralizing Antibodies","timeFrame":"Day 56","effectByArm":[{"arm":"IC51 and Placebo","deltaMin":192.2,"sd":null},{"arm":"IC51 and HAVRIX","deltaMin":202.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":11},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":65},"commonTop":["Headache","Nasopharyngitis","Fatique","Influenza like illness","Diarrhea"]}}